New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
06:03 EDTLXRXLexicon Pharmaceuticals reports Q4 EPS (5c), consensus (5c)
Reports Q4 revenue $200K, consensus $370K.
News For LXRX From The Last 14 Days
Check below for free stories on LXRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
07:55 EDTLXRXLexicon removed from Stifel Select List at Stifel
Stifel removed Lexicon from its Select List, citing what it sees as a lack of near-term data catalysts and limited visibility into a partnership for LX4211. The firm thinks the company is favorably positioned for a partnership, but that it's difficult to predict the timing of such a deal. It keeps a $4 price target and Buy rating on the shares.
April 14, 2014
08:59 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:25 EDTLXRXLexicon to host conference call
Subscribe for More Information
06:10 EDTLXRXLexicon achieves positive results in Type 1 diabetes clinical trial
Lexicon Pharmaceuticals announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. In the placebo-controlled, double-blind, 28-day study, LX4211 reduced the total daily mealtime bolus insulin dose by 32% compared to 6% for placebo, while significantly improving glycemic control with a mean HbA1c reduction of 0.55% in the LX4211-treated group compared to a reduction of only 0.06% with placebo. This improvement was accompanied by significant improvement in the time spent in a glucose range of 70-180 mg/dl, a significant reduction in time in hyperglycemic range, and no increase in hypoglycemia. Multiple measures indicated that LX4211 treatment resulted in reduced variability in blood glucose levels. Overall, LX4211 was well tolerated with no discontinuations of study medication due to adverse events.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use